Roche halts lung drug combo test
Roche has canned its exploratory combination of onartuzumab and Tarceva among previously treated, advanced non-small cell lung cancer patients with MET-positive tumors.
The company said in a statement Monday that it halted Phase-III studies “due to a lack of clinically meaningful efficacy.”
The company also said the findings have prompted a review of its other onartuzumab clinical trials.
Monday's news follows a Reuters story that indicates that although Roche and Novartis have been buddying up of late that a merger is not in the works.